The Official Website of the Long-Term Investor
Results 1 - 10 of 436 : 1 2 3 4 5 6 7 8 9 Next
Get RSS Feed for Pharmaceuticals
Have J&J's Approval Hopes Vanished?
Johnson & Johnson might have trouble sidestepping the competition.
Are 3 Failed Phase 3 Trials Enough?
The NExUS between ESCAPE and MISSION is failure.
5 Pharmaceutical Stocks With Significant Exposure to Europe
A fracture of the European monetary union could spell trouble for these five pharmaceutical stocks.
2 Reasons That Cystic Fibrosis Trumps Hep C
Vertex jumps on new cystic fibrosis data.
A Step Closer to Quadrific Sales
Gilead's Quad easily gets past the FDA advisory panel.
1 Biotech With 2 Binary Events in 2 Days
Two of Gilead's HIV drugs head in front of FDA advisory committee meetings.
Has InterMune Become the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
Will the FDA Approve Alexza's Adasuve?
Seems unlikely, given the data.
Pfizer Looks Fine Post-Tornado
Earnings statement gets jumbled up post-Lipitor, breakup.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK